Acne Drug Isotretinoin Linked to Rare Arthritis in Children, Review Finds

Isotretinoin has long been regarded as the most powerful weapon in dermatology against severe acne, transforming the lives of teenagers whose skin has resisted every antibiotic and topical cream. Yet a new scoping review published in the Archives of Dermatological Research is drawing attention to an underappreciated risk in the youngest patients: arthritis that appears after starting the drug. The review, led by Erica Rankin of Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine together with colleagues including Suzanne I. Riskin, systematically combed the medical literature for evidence of isotretinoin-associated arthritis in patients under the age of eighteen, and its conclusions carry practical weight for every clinician who prescribes this medication to adolescents.

The research team conducted their review under the PRISMA-ScR framework, the accepted reporting guideline for scoping reviews, which ensures a transparent and reproducible search strategy. They queried four major biomedical databases: PubMed, CINAHL, MEDLINE, and Web of Science. The inclusion criteria were deliberately narrow, targeting English-language primary studies published between 2000 and 2025 that evaluated arthritis following isotretinoin initiation in pediatric patients. By restricting the analysis to patients under eighteen, the authors aimed to isolate findings relevant to a population whose skeletons and immune systems are still developing, and in whom the risk-benefit calculus for any medication differs from that of adults.

Why does this matter clinically? Isotretinoin, a synthetic retinoid derived from vitamin A, works by dramatically shrinking the sebaceous glands, normalizing skin cell turnover, and reducing inflammation. It is the treatment of choice for severe nodulocystic acne and for acne that has failed other therapies. But retinoids are biologically potent molecules that influence cell differentiation far beyond the skin. The drug’s known musculoskeletal profile includes muscle aches, elevated creatine kinase levels, and, more rarely, changes to bone density and premature epiphyseal closure, the early fusion of growth plates that can affect limb development. Arthritis, particularly inflammation of the sacroiliac joints at the base of the spine, has surfaced repeatedly in case reports over the past two decades.

The pattern that emerges from the literature is striking in its specificity. Sacroiliitis, inflammation of the joint where the sacrum meets the pelvis, dominates the pediatric case reports. A 2020 case series in Pediatric Dermatology documented four adolescents who developed isotretinoin-induced sacroiliitis, and separate reports have described bilateral sacroiliitis in an adolescent with Klinefelter syndrome and unilateral sacroiliitis during systemic isotretinoin treatment. More recent work has extended these observations: a 2025 study in the Journal of Clinical Rheumatology examined isotretinoin-induced sacroiliitis using magnetic resonance imaging in a real-life clinical setting, and a 2025 analysis in Arthritis Research Therapy characterized the clinical features, treatment, and outcomes of isotretinoin-associated sacroiliitis across a broader cohort. These studies suggest the phenomenon is not a random scattering of anecdotes but a reproducible clinical entity.

The review also highlights the most dramatic presentations. Acne fulminans, a severe and ulcerating form of acne that can erupt suddenly, sometimes in tandem with systemic symptoms including fever and joint pain, is a recognized companion of isotretinoin therapy, particularly when the drug is started at high doses. Case reports describe adolescents who developed acne fulminans with bilateral acute sacroiliitis and hip synovitis, requiring biologic therapy with adalimumab to bring the inflammatory cascade under control. Other documented presentations include SAPHO syndrome, a rare disorder combining synovitis, acne, pustulosis, hyperostosis, and osteitis, in which isotretinoin has been implicated as a possible trigger or exacerbating factor. One fifteen-year-old boy developed antineutrophil cytoplasmic antibody-positive vasculitis alongside oligoarthritis, tendinitis, and myositis while on the drug, illustrating how broadly the inflammatory response can manifest.

What might explain the mechanism? The authors point to the biology of retinoids and their interaction with inflammatory pathways. Retinoic acid has been shown to increase the activity of matrix metalloproteinases, enzymes that degrade extracellular matrix components and play a central role in joint destruction in inflammatory arthritis. In cultured cells, retinol and retinoic acid upregulate MMP-2 activity through distinct signaling routes, providing a plausible molecular bridge between retinoid exposure and tissue inflammation. Isotretinoin is also known to modulate immune function and has been investigated for possible associations with other inflammatory conditions, including inflammatory bowel disease, a link first raised in a 2006 analysis in the American Journal of Gastroenterology. Whether the drug directly triggers autoinflammation or unmasks a pre-existing susceptibility in certain individuals remains an open question, and the review is careful not to overstate causality where the evidence rests on case reports.

That caution is warranted. The scoping review’s central finding is not that arthritis is common, but that it is rare yet clinically significant when it occurs. The authors emphasize that isotretinoin-associated arthritis may be particularly relevant for pediatric patients with severe inflammatory acne or underlying autoinflammatory conditions, groups in whom the immune system may already be primed for exaggerated responses. Distinguishing drug-induced joint inflammation from coincidental juvenile idiopathic arthritis, infection-related arthritis, or the musculoskeletal manifestations of the acne itself is diagnostically challenging, and the temporal relationship between drug initiation and symptom onset becomes the key clue. In several reported cases, symptoms improved or resolved after the drug was stopped, while others required immunosuppressive treatment ranging from methotrexate to tumor necrosis factor inhibitors.

For practicing dermatologists and pediatricians, the practical implications are concrete. Clinicians initiating isotretinoin in adolescents should counsel patients and families to report new joint pain, morning stiffness, or back pain promptly rather than dismissing these symptoms as growing pains or exercise soreness. Inflammatory back pain in a teenager on isotretinoin should prompt evaluation for sacroiliitis, ideally with magnetic resonance imaging, which is far more sensitive than plain radiography for detecting early inflammatory changes in the sacroiliac joints. The review also underscores the importance of documenting baseline musculoskeletal health and considering slower dose escalation in patients with risk factors, since several severe presentations occurred early in treatment at higher doses.

The authors are explicit about the limitations of the existing evidence base. Scoping reviews map what has been published rather than pooling data statistically, and the literature they surveyed consists largely of case reports, case series, and small observational studies rather than controlled trials. No datasets were generated or analyzed in the review itself, and the true incidence of isotretinoin-associated arthritis in children cannot be calculated from spontaneous case reports, which are subject to publication bias and underreporting. What the review establishes is the existence of a consistent signal, a recognizable clinical spectrum, and a set of treatment patterns that can guide clinicians when the complication arises.

The review’s authors call for increased clinician awareness and, crucially, further prospective research to identify at-risk populations and optimize management strategies. Prospective cohort studies following large numbers of isotretinoin-treated adolescents with standardized musculoskeletal assessments, including imaging at symptom onset, would allow incidence rates to be calculated and risk factors to be defined. Until such data exist, the review serves as a reminder that even the most familiar medications can surprise us, and that vigilance for rare adverse effects is not alarmism but good medicine. For the millions of teenagers who benefit from isotretinoin each year, the message is reassuring: severe joint complications remain uncommon. For the clinicians who prescribe it, the message is equally clear: listen to the joints as carefully as you examine the skin.

Subject of Research: Isotretinoin-associated arthritis in pediatric patients

Article Title: Incidence of isotretinoin-associated arthritis following isotretinoin initiation in pediatric patients: a scoping review

Article References: Rankin, E., Juriga, J., Voss, K., Gentry, C., Daily, A., Foss, J., Patel, A., Shepherd, D., Kluglein, K., & Riskin, S. I. (2026). Incidence of isotretinoin-associated arthritis following isotretinoin initiation in pediatric patients: a scoping review. Archives of Dermatological Research, 318(1), Article 401. https://doi.org/10.1007/s00403-026-04883-2

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04883-2

Keywords: isotretinoin, arthritis, sacroiliitis, pediatrics, acne vulgaris, acne fulminans, scoping review, adverse effects, retinoids, rheumatology, dermatology, juvenile idiopathic arthritis